8-K/A: Avinger Secures Strategic Partnership and $15 Million Investment to Expand into Greater China

Avinger has entered into a strategic partnership with Zylox-Tonbridge, including a $15 million investment, to expand its product distribution and manufacturing into the Greater China region.

Summary

• Avinger has partnered with Zylox-Tonbridge Medical Technology Co., Ltd. to distribute its products in Greater China, including mainland China, Hong Kong, Macao, and Taiwan.
• Zylox-Tonbridge will handle regulatory approvals and eventually manufacture Avinger's products locally.
• Avinger will receive royalties on sales of locally manufactured products, ranging from mid-single to high-single digit percentages based on gross revenue and product gross margin.
• The initial term of the license agreement is 20 years, with automatic extensions for additional 20-year terms.
• Zylox-Tonbridge will invest up to $15 million in Avinger through a private placement of common and preferred stock.
• The initial closing on March 5, 2024, involved a $7.5 million investment for common stock and Series F preferred stock.
• A further $7.5 million investment in Series G preferred stock is contingent on Zylox-Tonbridge's manufacturing facility being FDA registered and Avinger achieving $10 million in gross revenue within four consecutive quarters.
• Avinger has also amended its loan agreement with CRG Partners to extend the interest-only period and allow for payment of interest in kind.
• Avinger has exchanged all outstanding shares of its Series A Preferred Stock for Series A-1 Preferred Stock.
• Avinger has appointed Jonathon Zhong Zhao to its Board of Directors as part of the agreement.

Sentiment

Score: 8

Explanation: The document outlines a significant strategic partnership and investment, which is a positive development for the company. The terms of the agreement appear to be favorable, and the company has secured a substantial amount of funding. However, there are some risks and uncertainties associated with the milestones and regulatory approvals.

Positives

• The strategic partnership with Zylox-Tonbridge provides Avinger with access to the large Greater China market.
• The $15 million investment strengthens Avinger's financial position.
• The royalty structure provides a recurring revenue stream for Avinger.
• The extended interest-only period on the CRG loan provides financial flexibility.
• The ability to pay interest in kind through December 31, 2026, conserves cash.
• The agreement allows Avinger to potentially distribute Zylox-Tonbridge products in the U.S. and Germany.

Negatives

• The second tranche of the $7.5 million investment is contingent on Avinger achieving $10 million in gross revenue within four consecutive quarters and Zylox-Tonbridge's manufacturing facility being FDA registered.
• The conversion of preferred stock is subject to shareholder approval under Nasdaq rules.
• The royalty rates are mid-single to high-single digit percentages, which may not be substantial.
• The company is paying 2% and 5% of the gross proceeds to Piper and Cantor respectively as cash fees for financial advisory services.

Risks

• The success of the partnership depends on Zylox-Tonbridge's ability to obtain regulatory approvals and establish manufacturing capabilities.
• Avinger's ability to achieve the $10 million revenue milestone is uncertain.
• The conversion of preferred stock is subject to shareholder approval.
• The company is reliant on a single partner for its expansion into the Greater China market.
• There is a risk that the company may not be able to achieve the milestones required for the second tranche of funding.

Future Outlook

The company anticipates expanding its product distribution and manufacturing into the Greater China region through its partnership with Zylox-Tonbridge, and potentially distributing Zylox-Tonbridge products in the U.S. and Germany. The company also expects to receive additional funding upon achieving certain milestones.

Management Comments

• The document does not contain any direct quotes from management, but it does outline the strategic direction and financial transactions undertaken by the company.

Industry Context

This announcement reflects a trend of medical device companies seeking to expand into international markets, particularly China, to capitalize on growth opportunities. Strategic partnerships and investments are common strategies for achieving this expansion.

Comparison to Industry Standards

• The royalty rates of mid-single to high-single digits are within the typical range for medical device licensing agreements, but the specific terms will depend on the product and market.
• The $15 million investment is a significant amount for a company of Avinger's size, but the structure of the investment with tranches and milestones is common in the industry.
• The 20-year initial term of the license agreement is relatively long, indicating a strong commitment from both parties.
• Companies like Medtronic and Boston Scientific have also pursued similar strategies of international expansion through partnerships and acquisitions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will benefit from the potential growth and revenue opportunities in the Greater China market.
• Employees may see increased job security and opportunities as the company expands.
• Customers in Greater China will have access to Avinger's products.
• Suppliers may see increased demand for their products as Avinger's manufacturing expands.
• Creditors may see improved financial stability for Avinger due to the investment and partnership.

Next Steps

• Zylox-Tonbridge will pursue regulatory approvals for Avinger's products in Greater China.
• Zylox-Tonbridge will establish manufacturing capabilities for Avinger's products.
• Avinger will work to achieve the $10 million revenue milestone to trigger the second tranche of investment.
• Avinger will file a registration statement with the SEC for the resale of shares issued in the private placement.
• Avinger will seek shareholder approval for the conversion of preferred stock.

Key Dates

Keywords

Avinger, Zylox-Tonbridge, Strategic Partnership, License Agreement, Distribution Agreement, Private Placement, Greater China, Medical Devices, FDA, Preferred Stock, Royalty, Manufacturing